NE inhibitors, e.g., sivelestat sodium (ONO Pharmaceuticals), have been evaluated in clinical trials in patients with COPD (Hayakawa et al., 2010; Morjaria et al., 2010), and in acute lung injury patients (Yoshikawa et al., 2010). This evidence concerns the gene ELANE and chronic obstructive pulmonary disease.